NVAX ▲ +0.8% - Novavax, Inc. $NVAX NVAX - Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season Novavax shares rose 0.8% following the company's announcement of regulatory approvals for its XFG-adapted Nuvaxovid vaccine across major markets for the upcoming 2026-2027 vaccination season. The approvals in the U.S., EU, and Japan represent a continuation of Novavax's partnership strategy and expand its commercial footprint for the next flu-COVID combination vaccine cycle. These regulatory milestones position the company to capture market opportunity as health authorities prepare vaccination campaigns for the 2026-2027 season. 28-AUG-2026 08:30 AM ET